ReviewCurrent urology reports2015
Role of sodium fluoride PET imaging for identification of bony metastases in prostate cancer patients.
Review in Current urology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- PET imaging of recurrent and metastatic prostate cancer with novel tracers.Future oncology (London, England) · 2016Review
- Prostate-Specific Antigen and Prostate-Specific Antigen Kinetics in PredictingWorld journal of nuclear medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sodium fluoride (Na-F) PET/CT is an imaging technique which allows radiolabeled fluoride to help detect areas of bone turnover. Detecting metastatic prostate cancer earlier than is currently possible with standard imaging may help prevent unnecessary morbidity for patients and improve staging in an effort to more accurately select the appropriate therapy at an appropriate time. Na-F PET/CT has been investigated as a means to help detect osseous metastatic disease in prostate cancer. It is still unclear which clinical circumstances are beneficial for a patient to undergo Na-F PET/CT in addition to, or instead of, the current standard imaging. This review examines the most recent publications related to this topic.
Indexed as
Identifiers
25794498What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.